Navigation Links
The Quigley Corporation Reports First Quarter 2009 Results
Date:5/1/2009

DOYLESTOWN, Pa., May 1 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY) www.quigleyco.com today reported net sales of $4.0 million, for the first quarter ended March 31, 2009, compared to $5.3 million reported for the same period in 2008.

The decrease in net sales for the first quarter of 2009 reflects a market-wide decrease in consumer purchases of cold remedy products as reported by Information Resources Inc., ("IRI") data, general economic weakness and lower incidence of colds by consumers.

Net sales for the first quarter of 2009 reflect the benefits of the Kids-EEZE(R) Chest Relief product line, which was launched in August 2008. As part of ongoing initiatives to support consumer awareness, the Company continued to implement its advertising and targeted couponing campaign to promote the COLD-EEZE(R) brand.

The loss from continuing operations for the first quarter ended March 31, 2009 decreased to $2.2 million, or ($0.17) per share, compared to a loss from continuing operations of $2.4 million, or ($0.19) per share for the first quarter of 2008. The decrease in loss from continuing operations includes a reduction in total operating expenses of $1.6 million in the 2009 period.

Net loss for the first quarter ended March 31, 2009 was $2.2 million, or ($0.17) per share, compared to net loss of $1.6 million or ($0.12) per share, for the comparable period in 2008. The net loss for the first quarter of 2008 included a benefit on disposal of discontinued operations of $876,000 without which the net loss for the period would have been $2.4 million, or ($0.19) per share.

The Company continued to invest in Quigley Pharma, a wholly owned Ethical Pharmaceutical subsidiary deve
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
2. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
3. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
4. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
5. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
6. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
7. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
8. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
9. Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes
10. Protein Sciences Corporation Appoints New Board of Directors
11. Digirad Corporation Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... detection methods that can rapidly screen a large ... cell inside that population has been seriously lacking," ... In the Royal Society of Chemistry journal ... and his coworkers have developed a novel technique ... ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... and vegetables are often displayed in the popular ... also plenty of high-sugar foods. A new study ... is portrayed in children,s TV programmes as well ... dietary habits and weight status. , Steingerdur Olafsdottir,s ... in the popular Swedish children,s TV show Bolibompa. ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... abstract that will be presented on Wednesday at SLEEP ... Sleep Societies (APSS), finds a link between normal sleep ... Ancoli-Israel, PhD, of the University of California at San ... of age or older. Reports of use of ...
... 11 DaVita Inc., a leading,provider of kidney ... and disease (CKD), recently announced that Debbie Benner, ... DaVita(R) and Mary,Burgess, RD, Grant Program Manager for ... abstracts at the XIV International Congress on,Nutrition and ...
... first time, UCLA researchers have discovered that people with ... help store memory. Reported in the June 27 edition ... importance of early detection of the disorder, which afflicts ... Sleep apnea occurs when a blocked airway repeatedly halts ...
... nonprofit organization, has announced it is offering free,step-by-step assistance to uninsured ... its mission to improve the overall,health of Americans throughout the United ... sites or,calling its toll-free numbers:, -- For English: ... ...
... SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- Fresenius Medical ... in the Chinese,province of Sichuan. In addition to ... of $1.1 million in both cash and material ... by the natural disaster.,Fresenius Medical Care is providing ...
... workers revive unconscious passenger, SACRAMENTO, Calif., June ... saved the life of a 53-year-old,passenger on their ... The trio was among a group of ... to attend a contract bargaining session with their,employer, ...
Cached Medicine News:Health News:Normal sleep linked to successful aging 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2Health News:Memory loss linked to common sleep disorder 2Health News:Memory loss linked to common sleep disorder 3Health News:The CoverMe Foundation Offers Free, Step-By-Step Assistance to Connect Uninsured with Free or Reduced-Cost Health Care 2Health News:Fresenius Medical Care Supports Chinese Earthquake Victims 2Health News:UHW Members Save Man's Life On Flight 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... Ureteral Access Sheath, you can have all ... - plus an entirely new level of ... designed with a proprietary dual lumen design, ... channel for a variety of procedural steps ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
Medicine Products: